We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Celgene Backs Out of $55 Million Revlimid Settlement
Celgene Backs Out of $55 Million Revlimid Settlement
In an unusual move, Celgene has backed out of a $55 million settlement to clear accusations of anticompetitive behavior over its cancer treatments Revlimid and Thalomid, attorneys for the plaintiffs announced Wednesday.